Article Information
PubMed
Published By
History
- Received December 27, 2018
- Accepted February 12, 2019
- Published online April 17, 2019.
Copyright & Usage
Copyright © 2019 American Society for Microbiology. All Rights Reserved.
Editors and / or Reviewers
- Jae U. Jung, Editor, University of Southern California
Article Versions
- Accepted Manuscript version (February 20, 2019).
- You are viewing the most recent version of this article.
Author Information
- Ruchi Srivastavaa,
- Soumyabrata Roya,
- Pierre-Gregoire Coulona,
- Hawa Vaheda,
- Swayam Prakasha,
- Nisha Dhanushkodia,
- Grace J. Kima,
- Mona A. Fouladia,
- Joe Campoc,
- Andy A. Tengc,
- Xiaowu Liangc,
- Hubert Schaeferd and
- Lbachir BenMohameda,b,e
- aLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California, Irvine, School of Medicine, Irvine, California, USA
- bDepartment of Molecular Biology & Biochemistry, University of California, Irvine, Irvine, California, USA
- cAntigen Discovery Inc., Irvine, California, USA
- dIntracellular Pathogens, Robert Koch-Institute, Berlin, Germany
- eInstitute for Immunology, University of California, Irvine, School of Medicine, Irvine, California, USA
- Address correspondence to Lbachir BenMohamed, Lbenmoha{at}uci.edu.
R.S., S.R., P.-G.A.C., and H.V. contributed equally to this article.
Citation Srivastava R, Roy S, Coulon P-G, Vahed H, Prakash S, Dhanushkodi N, Kim GJ, Fouladi MA, Campo J, Teng AA, Liang X, Schaefer H, BenMohamed L. 2019. Therapeutic mucosal vaccination of herpes simplex virus 2-infected guinea pigs with ribonucleotide reductase 2 (RR2) protein boosts antiviral neutralizing antibodies and local tissue-resident CD4+ and CD8+ TRM cells associated with protection against recurrent genital herpes. J Virol 93:e02309-18. https://doi.org/10.1128/JVI.02309-18.